In order to understand the mechanism of action (MOA) of a drug, you first have to know the underlying biology of the disease. This is particularly important for new products, where you are often analyzing how you compare to competitors, and the strengths and weaknesses each may have in their MOA.
In anticipation of new data at the forthcoming American Society of Clinical Oncology (ASCO) meeting, Sally Church on Pharma Strategy Blog provides a review of two hematologic malignancies, indolent B-cell lymphoma and chronic lymphocytic leukemia (CLL).
In Sally’s post, she applies what we know about the underlying science to current drug therapies. One of her conclusions is that FCR (fludarabine, cyclophosphamide, rituximab) “is now very much the bedrock of treatment for patients with CLL and is based on a very solid rationale.”
For those interested in what new therapies are emerging for CLL, you’ll have to read further on Pharma Strategy Blog.
Sally is a regular attendee at the annual meetings of the American Society of Hematology (ASH) and ASCO, and has particular expertise in this area. Please feel free to contact us to find out how we can help you bring new hematology products to market.